Shaping Animal Health for the Next Decade Zoetis Investor Day May 25, 2023 Exhibit 99.2

Introduction Steve Frank Vice President, Investor Relations

Forward-Looking Statements This presentation contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance; future guidance, future operating models, disruptions in our global supply chain; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development; expected timing of product launches; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions, future use of cash, dividend payments and share repurchases, foreign exchange rates, tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. Non-GAAP Financial Information We use non-GAAP financial measures, such as adjusted net income, organic operational growth, adjusted net income margin, adjusted EBITDA margin, adjusted diluted EPS and operational results (which excludes the impact of foreign exchange) to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this presentation should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and revenue growth, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are available in the appendix to this presentation.

9:00 – 9:45 Our Strategy & Ambitions: Kristin Peck, CEO 9:45 – 10:15 Power of Our R&D: Robert Polzer, PhD, EVP and President of R&D 10:15 – 10:45 Delivering Our Value Proposition: Panel Discussion • Jeannette Ferran Astorga, EVP, Corporate Affairs, Communications and Chief Sustainability Officer • Jamie Brannan, EVP and President, International Operations and Aquaculture • Wafaa Mamilli, EVP, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health • Nick Ashton, EVP & President, Global Manufacturing and Supply 10:45 – 11:00 Break 11:00 – 11:30 Our Financial Roadmap: Wetteny Joseph, EVP and CFO 11:30 – 12:15 Q&A Agenda

Our Strategy and Ambitions Kristin Peck Chief Executive Officer

What you will hear today Building on Our Leadership in Animal Health We have the right strategy, talent and capabilities to shape and expand the future of Animal Health. Delivering Growth in a Dynamic and Resilient Industry Animal Health is an essential and attractive growth market, and we are confident in our ability to innovate and grow faster than the market. Driving Our Next Phase of Game Changing Franchises We are proven market makers, using internal R&D and business development to advance animal care and create durable and diverse franchises. Investing in Capabilities and Innovation that Differentiate Zoetis Continued investments in R&D, supply chain and commercial excellence will drive our next phase of growth, including the expansion of our diverse portfolio with market-leading franchises. Committed To Creating Value We are well-positioned to deliver on our value proposition, as we have done for the past 10 years, through revenue growth, strategic investments, margin expansion and capital return. 1 2 3 4 5

Building on Our Leadership in Animal Health

Our Purpose To nurture our world and humankind by advancing care for animals

Our Vision To be the most trusted and valued animal health company, shaping the future of animal care through our innovation, customer obsession and purpose-driven colleagues

Our Strategic Priorities Lead through innovation across our diverse portfolio Deliver an exceptional experience to delight our customers Power our business through digital solutions and data insights Support a workplace where our colleagues can thrive Advance sustainability in animal health for a better future Perform with excellence and agility

Our Core Beliefs Our colleagues make the difference Always do the right thing Customer obsessed Run it like you own it We are one Zoetis

Zoetis at a glance 70+ Years of Experience We provide: Medicines Vaccines Diagnostics Biodevices Genetic tests Precision animal health Note: Facts and figures shown are as of Dec. 31, 2022 1In addition, revenue associated with Client Supply Services and Human Health represents 1% of total 2022 revenue. $8.1B Annual revenue 7 Major product categories 8 Core animal species 100+ Countries where Zoetis products are sold 29 Manufacturing sites 64% Revenue from companion animal products1 Revenue from livestock products1 35% 1,430 Approximate R&D colleagues 4,200 Approximate field force members 13,800 Approximate colleagues worldwide

We remain committed to the four tenets of our Value Proposition Return excess capital to shareholders Grow revenue faster than the market Invest in innovation and growth capabilities Increase adjusted net income faster than revenue

Grow revenue faster than the market Grew revenue operationally 3% faster than the core animal health market1 since our IPO 1 Source: Vetnosis' estimated average annual growth rates from 2013 to 2022 in the core animal health market (which excludes diagnostics, genetic tests, biodevices and precision animal health) for Zoetis (~8%) as compared to estimates for the overall industry including Zoetis (~5%). Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange. 2 Targeted average over the forecast period Grow annual revenue mid-to-high single digits2 • Broaden existing billion-dollar franchises • Innovate and build new franchise opportunities • Expand across attractive emerging markets • Accelerate commercial excellence to take share Our track-record Path forward - next 3 to 5 years

Invest in innovation and growth capabilities >$4B1 Invested in R&D, building billion-dollar franchises and 15 blockbusters2 Acquired Strategic capabilities in Diagnostics, Aquaculture and other key areas 1 From 2013 to 2022; R&D investments cumulative. 2 Blockbuster products in Animal Health generate more than $100 million in annual sales 3 ROIC stands for Return On Invested Capital 4 Targeted average over the forecast period Drive ROIC3 accretion4 • Prioritize R&D investment in the highest ROIC opportunities • Transform the standard of care through innovative products • Increase supply chain capabilities, capacity and agility • Deliver greater value to vets, producers and pet owners Our track-record Path forward - next 3 to 5 years

Increase adjusted net income faster than revenue Grew adjusted net income faster than revenue annually Expanded margins >1250bps with our focused operating model and disciplined portfolio approach1 1 From 2013 to 2022 2 Targeted average over the forecast period Enable margin improvement2 • Expand revenue in higher margin product categories • Leverage scale to drive bottom line performance • Optimize and simplify to increase productivity and efficiency Our track-record Path forward - next 3 to 5 years